Related Experiment Video
Updated: Feb 5, 2026

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
Published on: July 1, 2020
Accelerated Pathways Work-Now What? A Survey of Payers in the United States
Barry Farrimond1, Jonathan J Fleming2,3, Mark Mathieu1
11 PAREXEL, Waltham, MA, USA.
Background:
The US FDA has developed numerous accelerated pathways (APs) to facilitate faster development and approval of innovative drugs addressing unmet needs.
Methods:
To gauge how payers in the United States view APs, PAREXEL and the Network for Excellence in Healthcare Innovation (NEHI) surveyed 20 national, regional, public, and private payers whose coverage decisions impact 228 million patients.
Results:
The survey shows that APs have created new challenges and concerns for payers, including greater difficulty valuing drugs that have less clinical information available at launch.
Conclusions:
Our survey indicates that policies must further the goal of getting needed new medicines to patients expeditiously, while managing the risks AP drugs entail for payers and, most importantly, patients. For developers, a trend toward value-based assessments of both AP and non-AP drugs by payers may require ever-earlier and more data-driven decision making about the value of new products in development.
More Related Videos
10:46Acute In Vivo Electrophysiological Recordings of Local Field Potentials and Multi-unit Activity from the Hyperdirect Pathway in Anesthetized Rats
Published on: June 22, 2017
07:43Methods for Image-based Surveys of Benthic Macroinvertebrates and Their Habitat Exemplified by the Drop Camera Survey for the Atlantic Sea Scallop
Published on: July 2, 2018
Related Concept Videos
Surveys
Introduction to Surveying, Plane Surveying and Geodetic Surveys
Errors and Mistakes in Surveying
Types of Surveys
Survey Safety
Accelerators
The effectiveness of calcium chloride can...